{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:02Z","timestamp":1791945902333,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2026,6]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T\n SNCA<\/jats:italic>\n mutation usually leads to a severe form of PD.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The aim of this work was to assess the possible use of serum NfL as a marker of ongoing neurodegeneration in A53T\u2010PD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using a propensity score matching\u2010based technique with data from the Parkinson's Progression Markers Initiative, we matched, in a 3:1 ratio, A53T\u2010PD participants to iPD patients and healthy control subjects (HCs) by age and disease duration, where applicable.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n After matching, 18 A53T\u2010PD, 54 iPD, and 54 HC subjects were analyzed. Serum NfL was higher in A53T\u2010PD (9.82 [8.02\u201318.1] pg\/ml) compared with HCs (7.54 [5.76\u201310.1],\n P<\/jats:italic>\n \u2009=\u20090.008) or iPD patients (8.59 [6.86\u201311.1],\n P<\/jats:italic>\n \u2009=\u20090.077) (overall\n P<\/jats:italic>\n \u2009=\u20090.049).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n A53T\u2010PD patients have high NfL levels, which could potentially be used as an outcome in clinical trials with disease\u2010modifying agents. \u00a9 2026 The Author(s).\n Movement Disorders<\/jats:italic>\n published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/mds.70236","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:05:39Z","timestamp":1772993139000},"page":"1580-1585","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.\n \n A53T\n SNCA<\/i>\n <\/scp>\n Mutation: Data from the Parkinson's Progression Markers Initiative Study"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-8472","authenticated-orcid":false,"given":"Nikolaos","family":"Papagiannakis","sequence":"first","affiliation":[{"name":"1st Department of Neurology, Eginition Hospital, Medical School National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-0717","authenticated-orcid":false,"given":"Christos","family":"Koros","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Eginition Hospital, Medical School National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina\u2010Maria","family":"Simitsi","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Eginition Hospital, Medical School National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3569-8990","authenticated-orcid":false,"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Eginition Hospital, Medical School National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and The Parkinson's Progression Markers Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/42166"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26615"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12836-w"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1534"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003680"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00385-5"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28779"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.04.016"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.805953"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.01.024"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.644"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005063"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1061096"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1465016"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.959261"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010084"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1237284"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.70236","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:02:15Z","timestamp":1791943335000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.70236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/mds.70236"],"URL":"https:\/\/doi.org\/10.1002\/mds.70236","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"2025-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}